• 1
    Holmes KV, Lai MMC. Coronaviridae and their replication. In: FieldsB, KnipeD, HowleyP, eds. Fields virology. 3rd edition. Philadelphia: Lippincott-Raven, 1996: 1075.
  • 2
    Peiris JSM, Lai ST, Poon LLM, Guan Y, Yam LYC, Lim W, Nicholls, et al. Coronavirus as a possible cause of severe acute respiratory syndrome. Lancet 2003; 361: 13191325.
  • 3
    Drosten C, Gunther S, Preiser W, van der Werf S, Brodt HR, Becker S, Rabenau H, et al. Identification of a novel coronavirus in patients with severe acute respiratory syndrome. N Engl J Med 2003; 348: 19671976.
  • 4
    Lee N, Hui D, Wu A, Chan P, Cameron P, Joynt GM, Ahuja A, et al. A major outbreak of severe acute respiratory syndrome in Hong Kong. N Engl J Med 2003; 348: 19861994.
  • 5
    Tsang KW, Ho PL, Ooi GC, Yee WK, Wang T, Chan-Yeung M, Lam WK, et al. A cluster of cases of severe acute respiratory syndrome in Hong Kong. N Engl J Med 2003; 348: 19771985.
  • 6
    WHO. Severe acute respiratory syndrome (SARS). Wkly Epidemiol Rec 2003; 78: 8183.
  • 7
    Peiris JSM, Chu CM, Cheng VCC, Chan KS, Hung IFN, Poon LLM, Law KI, et al. Clinical progression and viral load in a community outbreak of coronavirus-associated SARS pneumonia: a prospective study. Lancet 2003; 361: 17671772.
  • 8
    Kaita KDE, Pettigrew N, Minuk GY. Hepatic regeneration in humans with various liver disease as assessed by Ki-67 staining of formalin-fixed paraffin-embedded liver tissue. Liver 1997; 17: 1316.
  • 9
    Lau LT, Wang CG, Yu CH. Enhanced detection of the coronavirus associated with severe acute respiratory syndrome (SARS). Abstract presented at the ASEAN, China, Japan, and ROK (10+3) High-Level Symposium on Severe Acute Respiratory Syndrome (SARS) 2003, June 3–4, Beijing, China, 2003. p 3132.
  • 10
    Marra MA, Jones SJ, Astell CR, Holt RA, Wilson AB, Butterfield YSN, Khattra J, et al. The genome seqence of the SARS-associated coronavirus. Science 2003; 300: 13991404.
  • 11
    Rota PA, Oberste MS, Monroe SS, Nix WA, Campagnoli R, Icenogle JP, Penaranda S, et al. Characterization of a novel coronavirus associated with severe acute respiratory syndrome. Science 2003; 300: 13941399.
  • 12
    Ning Q, Liu M, Kongkham P, Lai MM, Marsden PA, Tseng J, Pereira B, et al. The nucleocapsid protein of murine hepatitis virus type 3 induces transcription of the novel fgl2 prothrombinase gene. J Biol Chem 1999; 274: 99309936.
  • 13
    Hirano N, Murakami T, Taguchi F, Fujiwara K, Matumoto M. Comparison of mouse hepatitis virus strains for pathogenicity in weanling mice infected by various routes. Arch Virol 1981; 70: 6973.
  • 14
    Knobler RL, Haspel MV, Oldstone MB. Mouse hepatitis virus type 4 (JHM strains) induced fatal central nervous system disease: genetic control and murine neuron as the susceptable site of disease. J Exp Med 1981; 153: 832843.
  • 15
    Lavi ED, Gilden H, Wroblewska Z, Rorke LB, Weiss SR. Experimental demyelination produced by the A59 strain of mouse hepatitis virus. Neurology 1984; 34: 597603.
  • 16
    Gallagher TM. Murine coronavirus spike glycoprotein: receptor binding and membrane fusion activities. Adv Exp Med Biol 2001; 494: 183192.
  • 17
    Gallagher TM, Buchmeier MJ. Coronavirus spike proteins in viral entry and pathogenesis. Virology 2001; 279: 371374.
  • 18
    Navas S, Seo SH, Chua MM, Sarma JD, Lavi E, Hingley ST, Weiss SR. Murine coronavirus spike protein determines the ability of the virus to replicate in the liver and cause hepatitis. J Virol 2001; 75: 24522457.
  • 19
    Ng EKO, Hui DS, Chan AKC, Hung ECW, Chiu RWK, Lee N, Wu A, et al. Quantitative analysis and prognostic implication of SARS-coronavirus RNA in the plasma and serum of patients with severe acute respiratory syndrome. Clin Chem 2003; 49: 19761980.
  • 20
    Poutanen SM, Low DE, Henry B, Finkelstein S, Rose D, Green K, Tellier R, et al. Identification of severe acute respiratory syndrome in Canada. N Engl J Med 2003; 348: 19952005.
  • 21
    Kronenberger B, Ruster B, Lee JH, Sarrazin C, Roth WK, Herrmann G, Zeuzem S. Hepatocellular proliferation in patients with chronic hepatitis C and persistenly normal or abnormal aminotransferase level. J Hepatol 2000; 33: 640647.
  • 22
    Hussein O, Szvalb S, Akker-Berman LMV, Assy N. Liver regeneration is not altered in patients with nonalcoholic steatohepatitis (NASH) when compared to chronic hepatitis C infection with similar grade of inflammation. Dig Dis Sci 2002; 47: 19261931.
  • 23
    Wright N, Alison M. The liver. In: WrightN, AlisonM, eds. The Biology Epithelial Cell Populations Volume 2. Oxford: University Press, 1984: 880956.
  • 24
    Wurm T, Chen H, Hodgson T, Britton P, Brooks G, Hiscox JA. Localization to the nucleolus is a common feature of coronavirus nucleoproteins, and the protein may disrupt host cell division. J Virol 2001; 75: 93459356.
  • 25
    Hiscox JA, Wurm T, Wilson L, Britton P, Cavanagh D, Brooks G. The coronavirus infectious bronchitis virus nucleoprotein localizes to the nucleolus. J Virol 2001; 75: 506512.
  • 26
    Huang DS, Emancipator SN, Fletcher DR, Lamm ME, Mazanec MB. Hepatic pathology resulting from mouse hepatitis virus S infection in severe combined immunodeficiency mice. Lab Anim Sci 1996; 42: 167173.
  • 27
    Liu C, Xu HY, Liu DX. Induction of caspase-dependent apoptosis in cultured cells by the avian coronavirus infectious bronchitis virus. J Virol 2001; 75: 64026409.
  • 28
    Eleouet JF, Slee EA, Saurini F, Castagne N, Poncet D, Garrido C, Solary E, et al. The viral nucleocapsid protein of transmissible gastroenteritis coronavirus (TGEV) is cleaved by caspase-6 and -7 during TGEV-induced apoptosis. J Virol 2000; 74: 39753983.
  • 29
    Ding JW, Ning Q, Liu MF, Lai A, Leibowitz J, Peltekian KM, Cole EH, et al. Fulminant hepatic failure in murine hepatitis virus strain 3 infection: tissue-specific expression of a novel fgl2 prothrombinase. J Virol 1997; 71: 92239230.
  • 30
    Nicholls JM, Poon LLM, Lee KC, Ng WF, Lai ST, Leung CY, Chu CM, et al. Lung pathology of fatal severe acute respiratory syndrome. Lancet 2003; 361: 17731778.
  • 31
    Chu CM. Treatment-Kaletra. Abstract Presented at the SARS Clinical Management Workshop. June 13–14, 2003, Hong Kong, China.
  • 32
    Corbett AH, Lim ML, Kashuba DM. Kaletra (lopinavir/ritonavir). Ann Pharmacother 2002; 36: 11931203.
  • 33
    Lafeuillade A, Hittinger G, Chadapaud S. Increased mitochondrial toxicity with ribavirin in HIV/HCV coinfection. Lancet 2001; 357: 280281.
  • 34
    Salmon-Ceron D, Chauvelot-Moachon L, Abad S, Silbermann B, Sogni P. Mitochondrial toxic effects and ribavirin. Lancet 2001; 357: 1803.
  • 35
    Soriano V. Liver disease in HIV: an update. PRN Notebook 2002; 7: 1015.
  • 36
    Benveniste O, Longuet P, Duval X, Moing VL, Leport C, Vilde JL. Two episodes of acute renal failure, rhabdomyolysis, and severe hepatitis in an AIDS patient successively treated with ritonavir and indinavir. Clin Infect Dis 1999; 28: 11801181.
  • 37
    Odile P, Olivier R, Jean C. Hepatotoxicity associated with ritonavir. Ann Intern Med 1998; 129: 670671.
  • 38
    Sagir A, Wettstein M, Oette M, Erhardt A, Haussinger D. Budesonide-induced acute hepatitis in an HIV-positive patient with ritonavir as a co-medication. AIDS 2002; 16: 11911192.
  • 39
    Juzo M, Kengo G, Masami Y. Severe hepatitis in patients with AIDS and haemophilia B treated with indinavir. Lancet 1997; 350: 364.
  • 40
    Ilyin GP, Langouet S, Rissel M, Delcros JG, Guillouzo A, Guguen-Guillouzo C. Ribavirin inhibits protein synthesis and cell proliferation induced by mitogenic factors in primary human and rat hepatocytes. HEPATOLOGY 1998; 27: 16871694.
  • 41
    Hoofnagle JH, Lau D, Conjeevaram H, Kleiner D, Di Bisceglie AM. Prolonged therapy of chronic hepatitis C with ribavirin. J Viral Hepat 1996; 3: 247252.
  • 42
    Dusheiko G, Main J, Thomas H, Reichard O, Lee C, Dhillon A, Rassam S, et al. Ribavirin treatment for patients with chronic hepatitis C: results of a placebo-controlled study. J Hepatol 1996; 25: 591598.
  • 43
    Wit FW, Weverling GJ, Weel J, Jurriaans S, Lange JM. Incidence of and risk factors for severe hepatotoxicity associated with antiretorviral combination therapy. J Infect Dis 2002; 186: 2331.
  • 44
    Gisolf EH, Dreezen C, Danner SA, Weel JL, Weverling GJ, Prometheus Study Group. Risk factors for hepatotoxicity in HIV-1-infected patients receiving ritonavir and saquinavir with or without stavudine. Clin Infect Dis 2000; 31: 12341239.
  • 45
    Mariannea S, Stephaniea V, Valentina D, Catherinea M, Michelb D, Patriceb C, Noelleb B, et al. Severe hepatic cytolysis: incidence and risk factors in patients treated by antiretroviral combinations Aquitaine cohort, France, 1996–1998. AIDS 1999; 13: 115151.